The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
After a slow 2017, first-quarter biopharma acquisition activity could signal a turnaround.
Biopharma acquisitions slump in 2017, but venture capital-backed buyouts provide hope.
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.
Pharma and biotech takeover activity slumps to a five-year low in 2017.
The summer lull proved even quieter than normal in 2017, as transaction volumes slumped to a decade low.
Fewer smaller transactions seems to be driving the dip in dealmaking, while options deals are proving more popular.
Either buyers are being pickier or the pool of targets is dwindling.
Uncertainties around US healthcare and tax reforms is being blamed for the drop in dealmaking.